MAZE THERAPEUTICS, INC. COMMON STOCK
NASDAQ: MAZE (Maze Therapeutics, Inc.)
Kemas kini terakhir: 6 jam lalu31.37
-1.06 (-3.27%)
| Penutupan Terdahulu | 32.43 |
| Jumlah Dagangan | 818,930 |
| Purata Dagangan (3B) | 737,145 |
| Modal Pasaran | 1,715,416,576 |
| Harga / Jualan (P/S) | 89.15 |
| Harga / Buku (P/B) | 4.13 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 9 Nov 2026 |
| Margin Operasi (TTM) | -820.82% |
| EPS Cair (TTM) | -2.62 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 13.92% |
| Nisbah Semasa (MRQ) | 14.14 |
| Aliran Tunai Operasi (OCF TTM) | -114.74 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -68.62 M |
| Pulangan Atas Aset (ROA TTM) | -21.98% |
| Pulangan Atas Ekuiti (ROE TTM) | -37.49% |
AISkor Stockmoo
| Nilai 30% | 0.0 |
| Hutang rendah. Keuntungan lemah. Kecairan jangka pendek mencukupi. Aliran tunai negatif. info | |
| Daripada penilaian laporan AI Insight kami tentang pulangan dijangka berbanding risiko. info | NA |
| Penilaian Relatif info | NA |
| Pertumbuhan Tersirat info | NA |
| Sejarah Penilaian info | NA |
| Pulangan atas Modal info | NA |
| Nilai Pegangan info | NA |
| Premium Risiko info | NA |
| Penilaian Pasaran info | NA |
| Masa 30% | 0.7 |
| Tiada aliran jelas sepanjang tahun lalu. Jauh di bawah paras tertinggi 52 minggu. info | |
| Aliran menaik: harga di atas purata bergeraknya, dan purata itu sedang meningkat. Harga hampir dengan purata itu. info | |
| Daripada analisis teknikal AI kami terhadap carta. info | NA |
| Corak Lilin info | NA |
| Sentimen 20% | 0.0 |
| Tiada harga sasaran terkini, jadi berdasarkan arah semakan harga sasaran. info | |
| Sentimen Pegangan info | NA |
| Sentimen Berita info | NA |
| Wang Pintar 20% | 3.2 |
| Institusi bersih +15.00% daripada saham dalam pemfailan 13F terkini: 90 pemegang menambah, 65 mengurang (suku berakhir 30 Sep 2026). info | |
| Kedudukan jual singkat +12.9% dari 31 Aug hingga 30 Oct 2026, 8.8 hari untuk tutup (FINRA). info | |
| Aktiviti Orang Dalam info | NA |
| Keadaan pasaran dan sektor lemah. | |
| Persekitaran pasaran berhati-hati. info | |
| Sektor ketinggalan berbanding pasaran. | |
| Tonggak-tonggak sependapat, jadi skor diperkukuh. | |
| Tidak dikira dalam skor | |
| Perolehan sesaham meningkat setiap tahun. Mencatat kerugian dalam tahun-tahun kebelakangan. info | |
| Di atas garis aliran jangka sederhana. info | |
| Harga hampir dengan purata 52 minggunya. Naik dalam tempoh 5 tahun. info | |
| Aliran naik bagi ketiga-tiga tempoh. Momentum jangka pendek semakin lemah. info | |
| Harga hampir dengan paras sokongan. Paras sokongan dan rintangan menurun. info | |
| Skor Akhir | 0.91 |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Maze Therapeutics, Inc. | Bercampur | Menaik |
Saham Serupa
| Stok | Modal Pasaran | DY | P/E (TTM) | P/B | Skor |
|---|---|---|---|---|---|
| MAZE | 2 B | - | - | 4.13 | 0.9 |
| PBLS | 3 B | - | - | 3.38 | 0.8 |
| LEGN | 3 B | - | - | 2.59 | -1.6 |
| PVLA | 2 B | - | - | 10.82 | 0.9 |
| IMCR | 1 B | - | - | 3.24 | -0.2 |
| GPCR | 1 B | - | - | 1.01 | -0.8 |
|
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 1.55% |
| % Dimiliki oleh Institusi | 111.81% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Trv Gp Iv, Llc | 30 Jun 2026 | 4,473,958 |
Tiada data dalam julat masa ini.
Institusi
Pemilikan institusi: 119.75%
| Kedudukan | Pemegang | Saham |
|---|---|---|
| Bertambah | 90 | 10,413,211 |
| Berkurang | 65 | 4,730,262 |
| Baharu | 23 | 4,423,613 |
| Dijual habis | 24 | 1,859,070 |
Pemfailan SEC 13F melalui Nasdaq, pemfailan terkini hingga 30 Sep 2026. Pemfailan tiba sehingga 45 hari selepas setiap suku.
Kedudukan Jual Singkat
| Penyelesaian | Saham | Hari untuk tutup |
|---|---|---|
| 30 Oct 2026 | 6,684,604 | 8.8 |
| 15 Oct 2026 | 7,527,939 | 10.1 |
| 30 Sep 2026 | 6,565,330 | 6.1 |
| 15 Sep 2026 | 5,678,289 | 10.4 |
| 31 Aug 2026 | 5,918,321 | 16.0 |
| 14 Aug 2026 | 5,988,933 | 16.2 |
Data jual singkat FINRA melalui Nasdaq, dilaporkan dua kali sebulan.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 09 Nov 2026 | Yahoo Finance |
Maze Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights
Enrollment completed in Phase 2 HORIZON trial of MZE829; data from all three cohorts expected in early 2027 Enrollment ongoing in Phase 2 CIPheR trial of MZE782 in PKU; topline data expected in 2027 Phase 2 trial of MZE782 in CKD on track for H1 2027 initiation Strong balance sheet with $477… |
| 04 Nov 2026 | Yahoo Finance |
Wall Street Analysts Predict a 93.92% Upside in Maze Therapeutics, Inc. (MAZE): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 93.9% in Maze Therapeutics, Inc. (MAZE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
| 03 Nov 2026 | Yahoo Finance |
Maze Therapeutics to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced that Jason Coloma, Ph.D., chief executive… |
| 19 Oct 2026 | Yahoo Finance |
What Makes Maze Therapeutics, Inc. (MAZE) a New Buy Stock
Maze Therapeutics, Inc. (MAZE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
| 19 Oct 2026 | Yahoo Finance |
Intel upgraded, PayPal downgraded: Wall Street's top analyst calls
Intel upgraded, PayPal downgraded: Wall Street's top analyst calls… |
| 19 Oct 2026 | Yahoo Finance |
How Much Upside is Left in Maze Therapeutics, Inc. (MAZE)? Wall Street Analysts Think 123.39%
The average of price targets set by Wall Street analysts indicates a potential upside of 123.4% in Maze Therapeutics, Inc. (MAZE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the… |
| 13 Oct 2026 | Yahoo Finance |
Pompe Disease Market Set for Expansion During the Forecast Period (2026-2036) as Growth is Fueled by Next-Generation ERTs, Newborn Screening, and Pipeline Innovation | DelveInsight
Recently published Pompe Disease Market Insights report includes a comprehensive understanding of current treatment practices, Pompe disease emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United… |
| 06 Oct 2026 | Yahoo Finance |
Maze Therapeutics to Present Data from MZE829 and MZE782 Programs at ASN Kidney Week 2026
Oral presentation will highlight previously reported Phase 2 HORIZON data for MZE829 in patients with APOL1-mediated kidney disease Two poster presentations will highlight preclinical research supporting the therapeutic potential of SLC6A19 inhibition in chronic kidney disease SOUTH SAN FRANCISCO… |
| 05 Oct 2026 | Yahoo Finance |
3 Small-Cap Stocks With Catalysts That Could Put Them in the Spotlight
Small-cap stocks Ascentage Pharma, Maze Therapeutics, and Pagaya Technologies show improving fundamentals, strong cash positions, and bullish analyst ratings amid shifting investor interest. |
| 28 Sep 2026 | Yahoo Finance |
Could Vertex Pharmaceuticals (VRTX)’s Kidney Breakthrough Unlock a New Opportunity for Maze Therapeutics (MAZE)?
On September 22, Truist analyst Danielle Brill identified a “significant positive readthrough” for Maze Therapeutics, Inc. (NASDAQ:MAZE) following positive Phase 2 topline data from Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). The data validates APOL1 inhibition in classic APOL1-mediated… |
| 25 Sep 2026 | Yahoo Finance |
Maze Therapeutics (MAZE) Shares Moved, So What Is Driving Attention Now?
Fresh Coverage Puts Maze Therapeutics in Focus Maze Therapeutics (MAZE) moved higher in pre-market trading on 23 September after CIBC began covering the clinical-stage kidney and metabolic disease specialist, with the share reaction unfolding alongside new kidney data from Vertex Pharmaceuticals.… |
| 23 Sep 2026 | Yahoo Finance |
Maze Therapeutics Shares Rise 2.9% After CIBC Initiates Coverage
Maze Therapeutics (NASDAQ:MAZE) shares rose 2. 9% in pre-market trading after CIBC initiated coverage of the clinical-stage biopharmaceutical company with an Outperformer rating and a $50 price target. |
| 22 Sep 2026 | Yahoo Finance |
The Surprise That Sent Vertex — And Its Chief Rival — Soaring
Vertex stock popped Tuesday — while shares of rival Maze Therapeutics skyrocketed — on a surprise expansion for their kidney disease drugs. |
| 22 Sep 2026 | Yahoo Finance |
Twin Moves: VRTX Rises On Kidney Disease Trial Results, MAZE Rallies Harder
Vertex on Tuesday announced results from the mid-stage trial of its experimental pill, inaxaplin, in two groups of patients with APOL1-mediated kidney disease. |
| 22 Sep 2026 | Yahoo Finance |
Vertex’s Kidney Drug Success Sparks a 22% Surge for This Rival Biotech
Maze Therapeutics stock jumped after Vertex Pharmaceuticals reported positive results for inaxaplin, boosting confidence in a rival treatment from Maze. |
| 15 Sep 2026 | Yahoo Finance |
SCYNEXIS Appoints Todd Minga, M.D., as Senior Vice President, Research & Development
Experienced biopharmaceutical and nephrology leader joins SCYNEXIS to advance its rare disease development programsJERSEY CITY, N.J., Sept. 15, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX) (the Company or SCYNEXIS), a clinical-stage biotechnology company dedicated to advancing innovative… |
| 11 Sep 2026 | Yahoo Finance |
Maze Therapeutics Chief Medical Officer Dumps Entire Direct Stake in the Company for $255,000
The executive liquidated his entire direct holdings as the stock plunged about 50% from its 52-week high. |
| 02 Sep 2026 | Yahoo Finance |
Maze Therapeutics to Participate in Three Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced that company management will participate… |
| Papar semua | ||
Isyarat Terkini corak lilin dan silang EMA
Persediaan Teknikal Sederhana
AI Analisis Teknikal
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |